BACKGROUND: Communication supports, referred to as augmentative and alternative communication (AAC), are an integral part of medical speech-language pathology practice, yet many providers remain unfamiliar with assessment and intervention principles. For patients with complex communication impairments secondary to neurodegenerative disease, AAC services differ depending on whether their condition primarily affects speech and motor skills (ALS), language (primary progressive aphasia) or cognition (Alzheimer's disease). This review discusses symptom management for these three conditions, identifying behavioral strategies, low- and high-tech solutions for implementation during the natural course of disease. These AAC principles apply to all neurodegenerative diseases in which common symptoms appear. OBJECTIVES: To present AAC interventions for patients with neurodegenerative diseases affecting speech, motor, language and cognitive domains. Three themes emerge: (1) timing of intervention: early referral, regular re-evaluations and continual treatment are essential; (2) communication partners must be included from the onset to establish AAC acceptance and use; and (3) strategies will change over time and use multiple modalities to capitalize on patients' strengths. CONCLUSIONS: AAC should be standard practice for adults with neurodegenerative disease. Patients can maintain effective, functional communication with AAC supports. Individualized communication systems can be implemented ensuring patients remain active participants in daily activities.
BACKGROUND: Communication supports, referred to as augmentative and alternative communication (AAC), are an integral part of medical speech-language pathology practice, yet many providers remain unfamiliar with assessment and intervention principles. For patients with complex communication impairments secondary to neurodegenerative disease, AAC services differ depending on whether their condition primarily affects speech and motor skills (ALS), language (primary progressive aphasia) or cognition (Alzheimer's disease). This review discusses symptom management for these three conditions, identifying behavioral strategies, low- and high-tech solutions for implementation during the natural course of disease. These AAC principles apply to all neurodegenerative diseases in which common symptoms appear. OBJECTIVES: To present AAC interventions for patients with neurodegenerative diseases affecting speech, motor, language and cognitive domains. Three themes emerge: (1) timing of intervention: early referral, regular re-evaluations and continual treatment are essential; (2) communication partners must be included from the onset to establish AAC acceptance and use; and (3) strategies will change over time and use multiple modalities to capitalize on patients' strengths. CONCLUSIONS: AAC should be standard practice for adults with neurodegenerative disease. Patients can maintain effective, functional communication with AAC supports. Individualized communication systems can be implemented ensuring patients remain active participants in daily activities.
Entities:
Keywords:
ALS; Augmentative and alternative communication; communication disorders; dementia; progressive aphasia
Authors: Andrea Bandini; Jordan R Green; Jun Wang; Thomas F Campbell; Lorne Zinman; Yana Yunusova Journal: J Speech Lang Hear Res Date: 2018-05-17 Impact factor: 2.297
Authors: Ana S Costa; Regina Jokel; Alberto Villarejo; Sara Llamas-Velasco; Kimiko Domoto-Reilley; Jennifer Wojtala; Kathrin Reetz; Álvaro Machado Journal: Alzheimer Dis Assoc Disord Date: 2019 Jan-Mar Impact factor: 2.703
Authors: Steffy E A Stans; Ruth J P Dalemans; Uta R Roentgen; Hester W H Smeets; Anna J H M Beurskens Journal: Health Expect Date: 2018-04-19 Impact factor: 3.377
Authors: Paul Nuyujukian; Jose Albites Sanabria; Jad Saab; Chethan Pandarinath; Beata Jarosiewicz; Christine H Blabe; Brian Franco; Stephen T Mernoff; Emad N Eskandar; John D Simeral; Leigh R Hochberg; Krishna V Shenoy; Jaimie M Henderson Journal: PLoS One Date: 2018-11-21 Impact factor: 3.240
Authors: Lawren VandeVrede; Peter A Ljubenkov; Julio C Rojas; Ariane E Welch; Adam L Boxer Journal: Neurotherapeutics Date: 2020-10 Impact factor: 7.620